Skip to content

Addiction research published in 2022

Page 3 of 5: studies 41 to 60 of 89, newest first. Back to the addiction overview

Studies

D-cycloserine (DCS) is Not Susceptible to Self-administration, unlike S-ketamine Using an Intravenous Self-administration Model in Naive and Ketamine-habituated Sprague-Dawley Rats

bioRxiv Preprint Server August 12, 2022 Daniel C Javitt, Jonathan C. Javitt preprint

OBJECTIVE N-methyl D-aspartate Receptor (NMDAR) antagonist antidepressants have known potential for abuse liability. The aim of this study was to evaluate the abuse liability of D-cycloserine (DCS), using a self-administration paradigm in which DCS was tested in its efficacy in substituting for ketamine in ketamine-dependent rats.

DOI: 10.1101/2022.08.12.503713 (opens in new tab) Full text (opens in new tab) D-cycloserine Dcs Low abuse potential Non-addictive +13

Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder

Journal of Psychedelic Studies August 5, 2022 John Clifton, Annabelle M. Belcher, Aaron D. Greenblatt et al. 6 citations

Abstract Background and aims There is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and perception of risk amongst...

On the independence between phenomenal consciousness and computational intelligence

arXiv Preprint Archive August 3, 2022 Eduardo C. Garrido-Merchán, Sara Lumbreras preprint

Consciousness and intelligence are properties commonly understood as dependent by folk psychology and society in general. The term artificial intelligence and the kind of problems that it managed to solve in the recent years has been shown as an argument to establish that machines experience some sort of consciousness. Following the analogy of Russell, if a machine is able to do what a...

Full text (opens in new tab) Artificial intelligence consciousness Machine awareness Cs.ai consciousness Cs.ai awareness +8

Dual action of ketamine confines addiction liability.

Nature August 2022 Linda D. Simmler, Yue Li, Lotfi C Hadjas et al.

Ketamine is used clinically as an anaesthetic and a fast-acting antidepressant, and recreationally for its dissociative properties, raising concerns of addiction as a possible side effect. Addictive drugs such as cocaine increase the levels of dopamine in the nucleus accumbens. This facilitates synaptic plasticity in the mesolimbic system, which causes behavioural adaptations and eventually...

A sacred plant of neuronal effect: the use of ibogaine in addiction treatments in Brazil

Anthropology of Consciousness July 8, 2022 Bruno Ramos Gomes, Luís Fernando Tófoli 2 citations

ABSTRACT This research qualitatively investigated four treatments for addiction in Brazil that use ibogaine as the main tool in the process. Ibogaine is a substance derived from an African plant, Tabernanthe iboga, traditionally used in its region of origin and which leads to intense sensations during its acute effects and also different experiences of oneself and the surrounding world in the...

A systematic literature review of clinical trials and therapeutic applications of ibogaine.

Journal of Substance Abuse Treatment July 1, 2022 Patrick Köck, Katharina Froelich, Marc Walter et al. 68 citations

Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive and somatic effects of the iboga alkaloids set them apart from classic hallucinogens like LSD, mescaline, and...

Associations between classic psychedelics and nicotine dependence in a nationally representative sample

Scientific Reports June 22, 2022 Grant Jones, Joshua Lipson, Matthew K. Nock 31 citations

Abstract Tobacco use is the single largest cause of preventable death worldwide, but none of the established treatments aimed at smoking cessation work for a majority of smokers. As such, there is an urgent need for interventions capable of reliably treating nicotine addiction. The use of classic psychedelics has been associated with lower odds of many forms of substance dependence. Here we...

Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research

Addiction Neuroscience June 22, 2022 Fúlvio Rieli Mendes, Cristiane Dos Santos Costa, Victor Distefano Wiltenburg et al. 55 citations

Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction has been noted as the last stage of a chronic disease that may impair brain reward circuit responses and affects personal and social life. Treatments for SUD face challenges including availability and limited pharmacological response, often resulting...

Traditional Amazonian medicine in addiction treatment: Qualitative results

SSM: Qualitative Research in Health June 4, 2022 David M. O’shaughnessy, Zoltán Sarnyai, Frances Quirk et al.

Traditional Amazonian medicine, and in particular the psychoactive substance ayahuasca, has generated significant research interest along with the recent revival of psychedelic medicine. Previously we published within-treatment quantitative results from a residential addiction treatment centre that predominately employs Peruvian traditional Amazonian medicine, and here we follow up that work...

Ketamine As A New Therapeutic Option For The Management Of Mental Disorders

European Psychiatry June 1, 2022 M. Turki, O. Abidi, S. Ellouze et al. 1 citation

Introduction Ketamine is routinely used for anesthetic induction because of its dissociative properties. Recently, it has attracted attention as a rapid-acting anti-depressant, but other studies have also reported its efficacy in the management of diverse psychiatric pathologies previously resistant to treatment. Objectives We aimed to review the efficacity of ketamine in the management of...

Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies.

European Archives of Psychiatry and Clinical Neuroscience June 1, 2022 Lucas Silva Rodrigues, Giordano Novak Rossi, Juliana Mendes Rocha et al. 48 citations

Ayahuasca is a hallucinogenic/psychedelic traditionally used for ritual and therapeutic purposes. One such therapeutic use is related to Substance Use Disorders (SUDs). A previous systematic review of preclinical and human studies published until 2016 suggested that ayahuasca and its alkaloids have therapeutic effects in the treatment of SUDs. To conduct an update of this previous review. A...

Possible Therapeutics Effects of Ayahuasca, a Psychedelic Compound

European Psychiatry June 1, 2022 L. Silva, L. Bravo

Introduction Ayahuasca is an hallucinogenic tea prepared from the Amazonian vine Banisteriopsis caapi and the leaves of the plant Psychotria Viridis. Banisteriopsis caapi contains monoamine oxidase inhibitors (MAO) that render the N, N-dimethyltryptamine (DMT) of Psychotria Viridis active. This brew is being used as a sacrament in syncretic religions in urban areas of Brazil and worldwide with...

Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin

SURG Journal June 1, 2022 Anthony Principe 1 citation

This review presents a general background of psilocybin pharmacology and discusses its uses in treating various mental health disorders such as depression, anxiety, obsessive-compulsive disorder, and addiction. A summary of preliminary clinical trials utilizing psilocybin in each disorder is presented, along with an analysis of the neurobiological mechanisms that could explain the results. The...

Ayahuasca Ritual, Personality and Sociality: Observational Research Conducted in a Substance Use Disorder Rehabilitation Center in Uruguay

Journal of Psychoactive Drugs May 4, 2022 Ismael Apud, Juan Scuro, Ignacio Carrera et al. 14 citations

The current article presents a mixed qualitative-quantitative observational study of the effect of ayahuasca ritual on subjective experiences and personality traits on participants of a center specialized in the treatment of substance use disorder in Uruguay. When comparing the psychological traits of ayahuasca participants to a control group, quantitative results using the...

The Effectiveness of Mindfulness-based Cognitive Therapy on the Level of Anxiety and Quality of Life in Women with Opioid Use Disorder

فصلنامه علمی و پژوهشی اعتیادپژوهی May 1, 2022 Paria Shakibayi, Parinaz Ghayuomi

‫ذهن‬ ‫بر‬ ‫مبتني‬ ‫درماني‬ ‫شناخت‬ ‫اثربخشي‬ ‫کيفيت‬ ‫و‬ ‫اضطراب‬ ‫سطح‬ ‫بر‬ ‫آگاهي‬ ‫افيوني‬ ‫مواد‬ ‫مصرف‬ ‫اختالل‬ ‫با‬ ‫زنان‬ ‫زندگي‬

Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey

Substance Use & Misuse April 25, 2022 Dimitri Daldegan-Bueno, Dóra Révész, Paulo Rogério Morais et al. 15 citations

Background: Preliminary evidence suggests that long-term ayahuasca use is associated with better psychosocial outcomes and less drug use; however, available data on the association between ayahuasca intake frequency and psychosocial outcomes is limited. Objectives: We sought to characterize and investigate the association of regular ayahuasca use, as compared to non-regular use, on licit...

ALTERED STATES OF CONSCIOUSNESS IN GAMBLING AND INTERNET GAMING DISORDERS AS A RISK FACTOR FOR ADDICTION

Psychological Applications and Trends April 22, 2022 Tetiana Zinchenko, Edward Shatochin

"In GD and IGD, both at the preclinical level of problem game and at the clinical level of pathological game, altered states of consciousness are observed during the game and shortly before. In the scientific literature, they are called flow-state, dark flow, game trance, game intoxication, and so on. During these states, the person loses touch with reality, the real life situation completely...

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

Molecules April 13, 2022 Henry Lowe, Ngeh J. Toyang, Blair Steele et al. 53 citations

The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA...

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

Scientific Reports April 7, 2022 Grant Jones, Jocelyn A. Ricard, Joshua Lipson et al. 56 citations

Abstract Opioid use disorder (OUD) is a major source of morbidity and mortality in the U.S. and there is a pressing need to identify additional treatments for the disorder. Classic psychedelics (psilocybin, peyote, mescaline, LSD) have been linked to the alleviation of various substance use disorders and may hold promise as potential treatments for OUD. The aim of this study was to assess...